Escitalopram and amitriptyline lengthen QTc, but antidepressants did not raise early cardiac events

Design

IPD network meta-regression of 35 RCTs plus aggregate meta-analysis of 139 RCTs

Population

8,679 adults with major depression (IPD); 52,398 for cardiovascular events

Primary outcome

Change in QTcF over the first 8 weeks

Effect

Escitalopram +8.7 ms (95% CrI 1.6–15.8); amitriptyline +5.3 ms (0.8–9.8); MACE risk difference 0.01%

This individual participant data analysis pooled 35 double-blind trials (8,679 adults with major depression) with ECG data for placebo and 10 antidepressants, adjusting for baseline QTc, age, sex, BMI, potassium and kidney function. A separate aggregate analysis looked at early major adverse cardiovascular events across 139 trials (52,398 participants).

Against placebo, escitalopram lengthened QTc by 8.7 ms (95% credible interval 1.6–15.8) and amitriptyline by 5.3 ms (0.8–9.8) over the first eight weeks. Venlafaxine and vortioxetine were most often associated with the smallest changes. Effects varied widely between individuals, especially for escitalopram, fluoxetine and mirtazapine. Early major cardiovascular events and non-suicidal death did not differ from placebo (risk difference 0.01%, −0.01% to 0.02%).

The QT effect is real but modest, and early hard events were not increased in trial populations. Trials exclude many high-risk patients, so the practical use is choosing a lower-QT agent in someone who already has risk factors.

• In patients with a long baseline QTc, low potassium, kidney impairment or other QT drugs, avoid escitalopram and amitriptyline first line.
• Consider venlafaxine or vortioxetine where QT prolongation is a concern.
• Check an ECG and electrolytes before starting escitalopram in patients with cardiac risk factors.
• Reassure lower-risk patients: early major cardiovascular events were not increased in 52,398 trial participants.
• Remember the QT effect varies widely between individuals, so one normal ECG does not guarantee the next.

Why it matters

It gives a ranked, risk-adjusted basis for antidepressant choice in patients with cardiac vulnerability.

Don't overread it

Trial populations exclude high-risk patients, so the reassurance on cardiac events applies to them, not to everyone.

The statistics, in plain English

A credible interval is the Bayesian equivalent of a confidence interval; for escitalopram it runs from 1.6 to 15.8 ms, so the true effect could be small or clinically relevant. Trials enrol relatively healthy people and last weeks, so 'no increase in early events' does not cover older, sicker patients or long-term use.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.